Company intelligence / Profile preview
Suzhou Fundamenta Therapeutics
Suzhou, Jiangsu, Chinapharmaceutical-technology.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Suzhou Fundamenta Therapeutics is advancing allogeneic CAR-T therapies targeting hematologic malignancies and autoimmune diseases. Lead programs are in early clinical development with promising transition rates for their indications. No late-stage or commercialized products as of May 2025.
- Therapeutic areas
- OncologyHematology
- Modalities
- Allogeneic CAR-T cell therapyTCR therapyMonoclonal antibodies
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Collaboration with Zhejiang University on ThisCART19A program
Beyond the preview
Go deeper on Suzhou Fundamenta Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Suzhou Fundamenta Therapeutics.